PL3002294T3 - Fragmenty peptydowe do indukowania syntezy białek macierzy zewnątrzkomórkowej - Google Patents

Fragmenty peptydowe do indukowania syntezy białek macierzy zewnątrzkomórkowej

Info

Publication number
PL3002294T3
PL3002294T3 PL15188894T PL15188894T PL3002294T3 PL 3002294 T3 PL3002294 T3 PL 3002294T3 PL 15188894 T PL15188894 T PL 15188894T PL 15188894 T PL15188894 T PL 15188894T PL 3002294 T3 PL3002294 T3 PL 3002294T3
Authority
PL
Poland
Prior art keywords
seq
extracellular matrix
peptide fragments
matrix proteins
pkgp
Prior art date
Application number
PL15188894T
Other languages
English (en)
Inventor
Scott Harris
Timothy Falla
Lijuan Zhang
Original Assignee
Helix Biomedix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix, Inc. filed Critical Helix Biomedix, Inc.
Publication of PL3002294T3 publication Critical patent/PL3002294T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
PL15188894T 2006-06-13 2007-06-12 Fragmenty peptydowe do indukowania syntezy białek macierzy zewnątrzkomórkowej PL3002294T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81328406P 2006-06-13 2006-06-13
EP07796001A EP2027152B1 (en) 2006-06-13 2007-06-12 Peptide fragments for inducing synthesis of extracellular matrix proteins
EP15188894.8A EP3002294B8 (en) 2006-06-13 2007-06-12 Peptide fragments for inducing synthesis of extracellular matrix proteins
EP11175264.8A EP2402369B1 (en) 2006-06-13 2007-06-12 Peptide fragments for inducing synthesis of extracellular matrix proteins

Publications (1)

Publication Number Publication Date
PL3002294T3 true PL3002294T3 (pl) 2018-08-31

Family

ID=38664422

Family Applications (4)

Application Number Title Priority Date Filing Date
PL15188894T PL3002294T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydowe do indukowania syntezy białek macierzy zewnątrzkomórkowej
PL07796001T PL2027152T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
PL11175264T PL2402369T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
PL11175263T PL2409988T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukcji syntezy białek macierzy zewnątrzkomórkowej

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL07796001T PL2027152T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
PL11175264T PL2402369T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
PL11175263T PL2409988T3 (pl) 2006-06-13 2007-06-12 Fragmenty peptydów do indukcji syntezy białek macierzy zewnątrzkomórkowej

Country Status (19)

Country Link
US (5) US8110658B2 (pl)
EP (5) EP2402369B1 (pl)
JP (2) JP5535620B2 (pl)
CN (2) CN101472944B (pl)
AT (1) ATE533785T1 (pl)
AU (1) AU2007258387B2 (pl)
BR (2) BRPI0713153B8 (pl)
CA (4) CA2947349A1 (pl)
CY (1) CY1112241T1 (pl)
DK (3) DK2402369T3 (pl)
ES (4) ES2375413T3 (pl)
HK (5) HK1128700A1 (pl)
HU (2) HUE027273T2 (pl)
MX (2) MX2008016011A (pl)
PL (4) PL3002294T3 (pl)
PT (2) PT2409988E (pl)
RU (2) RU2501807C2 (pl)
SI (2) SI2027152T1 (pl)
WO (1) WO2007146269A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402369B1 (en) * 2006-06-13 2015-11-25 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins
PL2065029T3 (pl) * 2007-11-30 2013-09-30 Evonik Degussa Gmbh Kompozycja do higieny osobistej i kosmetyczna, zawierająca tetrapeptydy z motywami GX1X2G, PX1X2P lub PX1X2K
WO2009111471A2 (en) * 2008-03-03 2009-09-11 Henry Ford Health System Collagen-derived peptide as biomarker, therapeutic agent and target
US9850274B2 (en) * 2008-12-30 2017-12-26 Gkl-Biotec Ag Peptide combination
WO2011044443A2 (en) * 2009-10-09 2011-04-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Matricryptic ecm peptides for tissue reconstruction
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
NZ711281A (en) 2013-02-14 2017-12-22 Helix Biomedix Inc Short bio-active peptides for promoting wound healing
AU2014229557B2 (en) * 2013-03-13 2017-12-07 Anteis Sa Peptides for skin rejuvenation and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
BR112015031018B1 (pt) 2013-06-14 2023-03-07 Helix Biomedix Inc Composição compreendendo um tetrapeptídeo para tratamento de condições da pele
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
AU2016301391B2 (en) 2015-08-04 2022-07-28 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR101916522B1 (ko) 2015-09-25 2018-11-08 경상대학교산학협력단 굴 가수분해물의 제조방법 및 이로부터 분리된 펩타이드
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
CN110023326A (zh) 2016-09-23 2019-07-16 杜克大学 具有lcst行为的非结构化无重复多肽
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
JP6489486B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 ペンタペプチド／ヘキサペプチドにより変形性関節症を治療するための新規用途
JP6489487B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 テトラペプチド−３ ｇｅｋｇまたはペンタペプチド−３ ｇｅｋｇｆにより変形性関節症を治療するための新規用途
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000598A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4140473A1 (en) * 2021-08-27 2023-03-01 The Boots Company plc Cosmetic compositions
CN114437238B (zh) * 2022-01-26 2024-03-26 浙江工业大学 胶原蛋白肽-牛乳铁蛋白肽融合蛋白、基因及其表达方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU466760B2 (en) * 1972-03-14 1975-11-06 Takeda Chemical Industries Ltd. Process for producing peptide
US5064430A (en) * 1985-10-31 1991-11-12 Uab Research Foundation Polynonapeptide bioelastomers having an increased elastic modulus
JP2573006B2 (ja) * 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
JP2820750B2 (ja) * 1988-04-21 1998-11-05 ユーエービー リサーチ ファウンデイション 創傷治療部位における癒着の発生からの保護に適するバイオエラストマー材料
AU5433190A (en) 1989-04-10 1990-11-16 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
US5679770A (en) * 1991-11-08 1997-10-21 Mochida Pharmaceutical Co., Ltd. Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
IL104954A (en) * 1993-03-04 2006-08-01 Yissum Res Dev Co Use of osteogenic oligopeptides in the preparation of pharmaceutical compositions for the treatment of bone diseases and some such novel oligopeptides, pharmaceutical compositions containing them and their preparation
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
JPH07227281A (ja) * 1994-02-15 1995-08-29 Agency Of Ind Science & Technol ペプチダーゼ及びその製造法
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
US6159940A (en) * 1996-02-28 2000-12-12 Immunotech Developments Inc. Method for modulating hemopoiesis
DE19651099A1 (de) * 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
EP0858808B1 (en) * 1997-01-17 2003-04-02 Johnson & Johnson Medical Ltd. Peptides for use in wound treatment
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity
US6747135B1 (en) * 1998-10-16 2004-06-08 The Board Of Trustees For The Leland Stanford Junior University Fluorescent dye binding peptides
US6492326B1 (en) * 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
CA2276542C (en) * 1999-06-28 2013-07-30 Vladislav I. Deigin Novel peptide, a method for its preparation and a pharmaceutical composition containing the peptide
CN1280983A (zh) * 1999-07-16 2001-01-24 王革 白细胞介素－11的衍生物及其制备方法
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
AU2001255448A1 (en) * 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
US20030166510A1 (en) * 2000-10-11 2003-09-04 Pickart Loren R. Methods and compositions for increasing skin remodeling
GB0029777D0 (en) * 2000-12-06 2001-01-17 Regen Therapeutics Plc Peptides
AU2002255952A1 (en) 2001-03-28 2002-10-15 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7186693B2 (en) * 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7041506B2 (en) * 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
EP1534308A4 (en) * 2001-11-28 2007-03-14 Becton Dickinson Co PEPTIDES WITH INHIBITORY ACTION OF GROWTH
WO2003064620A2 (en) * 2002-01-31 2003-08-07 Irm, Llc Hepsin substrates and prodrugs
JP2006502971A (ja) * 2002-05-03 2006-01-26 ミレニアム バイオロジックス インコーポレーテッド 結合組織刺激ペプチド
CA2498329A1 (en) * 2002-09-09 2004-03-18 University Of Cincinnati Methods of cardiovascular disease assessment in an individual
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
TWI256893B (en) * 2003-03-25 2006-06-21 Fancl Corp Composition for promoting production of type I collagen and/or elastin
DE10339180A1 (de) * 2003-08-21 2005-03-24 Deutsche Gelatine-Fabriken Stoess Ag Kollagenhydrolysat
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
JP2005245285A (ja) * 2004-03-03 2005-09-15 National Institute Of Advanced Industrial & Technology コラーゲン分解物の製造方法
DE202004012807U1 (de) * 2004-08-13 2004-10-21 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit DNA-Reparaturenzymen und Oligopeptiden
DE102004055541A1 (de) * 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
DE102004050563A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Kosmetische und der dermatologische Zusammensetzungen mit Wirkstoffen für einen verbesserten Hautkomfort
DE102005000868A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Zusammensetzungen mit Inhibitoren der Prostaglandin- und/oder Leukotrien-Synthese in Kombination mit Stimulatoren der Freisetzung kutaner Neuromediatoren
WO2006028993A2 (en) * 2004-09-02 2006-03-16 Vanderbilt University Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
GB2434367B (en) * 2004-10-05 2010-05-12 Diversa Corp Improved vaccines
WO2006042661A2 (en) * 2004-10-18 2006-04-27 Cognis France S.A.S Oligopeptides and their use in cosmetics
WO2006048339A2 (en) * 2004-11-04 2006-05-11 L'oréal Cosmetic composition comrising an active agent and a urea compound
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
FR2884418B1 (fr) * 2005-04-15 2008-11-21 Soc Extraction Principes Actif Utilisation d'un peptide comme principe actif amincissant
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
DE102005063062A1 (de) * 2005-12-29 2007-07-05 Henkel Kgaa Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
US7807625B2 (en) * 2006-01-18 2010-10-05 Grant Industries, Inc Anti-wrinkle composition
EP2402369B1 (en) * 2006-06-13 2015-11-25 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins

Also Published As

Publication number Publication date
HK1128700A1 (en) 2009-11-06
EP2402369B1 (en) 2015-11-25
HK1217346A1 (zh) 2017-01-06
PL2409988T3 (pl) 2015-12-31
EP2027152B1 (en) 2011-11-16
MX361694B (es) 2018-12-10
DK2402369T3 (en) 2016-02-01
ES2545219T3 (es) 2015-09-09
CA2655116C (en) 2016-12-13
EP2027152A2 (en) 2009-02-25
CY1112241T1 (el) 2015-12-09
US20070299015A1 (en) 2007-12-27
CA2947353A1 (en) 2007-12-21
PL2027152T3 (pl) 2012-04-30
BRPI0713153B8 (pt) 2021-05-25
US20170157196A1 (en) 2017-06-08
JP5535620B2 (ja) 2014-07-02
US20120093740A1 (en) 2012-04-19
US8110658B2 (en) 2012-02-07
EP2402369A3 (en) 2012-05-16
US8962798B2 (en) 2015-02-24
US20140066380A1 (en) 2014-03-06
JP2014129369A (ja) 2014-07-10
EP2409988A2 (en) 2012-01-25
CN104017071B (zh) 2017-08-15
BR122018002612B8 (pt) 2021-07-27
ES2680022T3 (es) 2018-09-03
HK1210791A1 (en) 2016-05-06
HK1161600A1 (zh) 2012-07-27
EP2940042A2 (en) 2015-11-04
EP3002294B8 (en) 2018-05-16
EP3002294A2 (en) 2016-04-06
HUE026698T2 (en) 2016-07-28
PL2402369T3 (pl) 2016-05-31
US8658764B2 (en) 2014-02-25
MX2008016011A (es) 2009-02-13
CA2947349A1 (en) 2007-12-21
JP2009539987A (ja) 2009-11-19
AU2007258387A2 (en) 2009-02-19
PT2402369E (pt) 2016-02-19
EP2409988B1 (en) 2015-07-22
PT2409988E (pt) 2015-10-12
HK1161599A1 (en) 2012-07-27
US10376557B2 (en) 2019-08-13
CN101472944A (zh) 2009-07-01
EP3002294A3 (en) 2016-06-22
EP2402369A2 (en) 2012-01-04
ES2557402T3 (es) 2016-01-25
WO2007146269A2 (en) 2007-12-21
SI2027152T1 (sl) 2012-03-30
BR122018002612B1 (pt) 2021-01-19
EP2409988A3 (en) 2012-05-09
CN101472944B (zh) 2014-05-28
RU2009100884A (ru) 2010-07-20
SI2409988T1 (sl) 2015-10-30
AU2007258387B2 (en) 2012-08-16
BRPI0713153A2 (pt) 2012-03-27
JP5844834B2 (ja) 2016-01-20
CN104017071A (zh) 2014-09-03
ES2375413T3 (es) 2012-02-29
CA2655116A1 (en) 2007-12-21
CA2835369A1 (en) 2007-12-21
US9447143B2 (en) 2016-09-20
HUE027273T2 (en) 2016-10-28
US20150094270A1 (en) 2015-04-02
EP2940042A3 (en) 2016-02-17
RU2011141572A (ru) 2013-04-20
CA2835369C (en) 2017-01-31
BRPI0713153B1 (pt) 2019-05-14
AU2007258387A1 (en) 2007-12-21
ATE533785T1 (de) 2011-12-15
RU2501807C2 (ru) 2013-12-20
EP3002294B1 (en) 2018-03-28
WO2007146269A3 (en) 2008-08-14
DK2027152T3 (da) 2012-02-20
DK2409988T3 (en) 2015-09-14
RU2441877C2 (ru) 2012-02-10

Similar Documents

Publication Publication Date Title
EP3002294B8 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
MX2009010610A (es) Dominio de enlace especifico de especies cruzadas.
IL163970A0 (en) Dedifferentiated, programmable stemcells of monocytic origin, and their production and use
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
TN2009000190A1 (en) Lingo binding molecules and pharmaceutical use thereof
JP2009539987A5 (pl)
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
HK1065447A1 (en) Stimulation of in vivo production of proteins withformulation comprising leucine
IN2012DN02981A (pl)
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
NZ596501A (en) Casb7439 constructs
JO2229B1 (en) Stem cells are programmable, distinctly regenerative, of single-core cell origin, production, and use
WO2008032054A3 (en) Composite material comprising a tissue matrix compound and a bioactive glass
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
NZ589743A (en) Anxiolytic composition containing alphas1-casein-derived peptides
MX2010005597A (es) Péptidos inmunoreguladores novedosos, composiciones y usos de los mismos.
GB201018125D0 (en) Peptide
ATE544779T1 (de) Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten